Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Concerns about omissions in the data presented

被引：0
|
作者：
Kennedy, RD [1 ]
Cuthbert, RG [1 ]
Kettle, PJ [1 ]
Morris, TCM [1 ]
机构：
[1] Queens Univ Belfast, Belfast City Hosp, Belfast, Antrim, North Ireland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2001年 / 19卷 / 06期
关键词：
D O I：
10.1200/JCO.2001.19.6.1884
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1884 / 1884
页数：1
相关论文
共 50 条
  • [31] High-dose intense doxorubicin-based regimens in aggressive non-Hodgkin's lymphoma: A systematic overview
    Azim, H. A.
    Malek, R. A.
    Santoro, L.
    Gandini, S.
    Bociek, R. G.
    Azim, H. A., Jr.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] Non-pegylated liposomal doxorubicin (Myocet®) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma
    Dell'olio, Matteo
    Scalzulli, Rosario Potito
    Sanpaolo, Grazia
    Nobile, Michele
    Mantuano, Francesco Saverio
    La Sala, Antonio
    D'Arena, Giovanni
    Miraglia, Eustachio
    Lucania, Anna
    Mastrullo, Lucia
    Nicola, Cascavilla
    LEUKEMIA & LYMPHOMA, 2011, 52 (07) : 1222 - 1229
  • [33] VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group
    Santini, G
    Coser, P
    Congiu, AM
    Salvagno, L
    De Souza, C
    Sertoli, MR
    Olivieri, A
    Chisesi, T
    Rubagotti, A
    Truini, M
    Contu, A
    Porcellini, A
    Zambaldi, G
    Nati, S
    Marino, G
    Rizzoli, V
    HAEMATOLOGICA, 2000, 85 (02) : 160 - 166
  • [34] Rituximab monotherapy is effective in patients with poor risk refractory aggressive non-Hodgkin's lymphoma
    Rothe, A
    Schulz, H
    Elter, T
    Engert, A
    Reiser, M
    HAEMATOLOGICA, 2004, 89 (07) : 875 - 876
  • [35] Survival benefit of high dose therapy over sequential chemotherapy in poor risk aggressive non-Hodgkin's lymphoma. Final analysis of the prospective LNH87-2 protocol. A gela study.
    Haioun, C
    Lepage, E
    Gisselbrecht, C
    Salles, G
    Coiffier, B
    Brice, P
    Bosly, A
    Morel, P
    Nouvel, C
    Tilly, H
    Lederlin, P
    Sebban, C
    Briere, J
    Gaulard, P
    Reyes, F
    BLOOD, 1999, 94 (10) : 610A - 610A
  • [36] High-dose therapy with peripheral blood progenitor cell support in patients with non-Hodgkin's lymphoma
    Haas, R
    Murea, S
    Goldschmidt, H
    Dohner, H
    Moos, M
    Witt, B
    Eugenhart, R
    Wannenmacher, M
    Hunstein, W
    STEM CELLS, 1995, 13 : 28 - 35
  • [37] High-dose therapy followed by bone marrow transplantation for relapsed follicular non-Hodgkin's lymphoma
    Schouten, IC
    Raemaekers, JJM
    KluinNelemans, HC
    vanKamp, H
    Mellink, WAM
    vantVeer, MB
    ANNALS OF HEMATOLOGY, 1996, 73 (06) : 273 - 277
  • [38] Intensive sequential chemotherapy followed by rituximab in poor-risk aggressive non-Hodgkin's lymphoma: Preliminary results of the ISC 98 trial.
    Bouabdallah, R
    Sebban, C
    Coso, D
    Vey, N
    Biron, P
    Lepeu, G
    Chabannon, C
    Xerri, L
    Faucher, C
    Stoppa, AM
    Gastaut, A
    Maraninchi, D
    BLOOD, 2002, 100 (11) : 296B - 296B
  • [39] Initial high-dose sequential chemotherapy in the treatment of aggressive non-Hodgkin lymphomas with risk factors
    Welt, A
    Anhuf, J
    Krawczyk, C
    Fossa, A
    Stuschke, M
    Kloke, O
    Schütte, J
    Westerhausen, M
    Sack, H
    Seeber, S
    Nowrousian, MR
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 237 - 237
  • [40] High-dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma
    Buckstein, Rena
    Kerbel, Robert S.
    Shaked, Yuval
    Nayar, Rakesh
    Foden, Cindy
    Turner, Ruth
    Lee, Christine R.
    Taylor, Diane
    Zhang, Liying
    Man, Shan
    Baruchel, Sylvain
    Stempak, Diana
    Bertolini, Francesco
    Crump, Michael
    CLINICAL CANCER RESEARCH, 2006, 12 (17) : 5190 - 5198
12345